🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Business news, market intelligence, and global industry analysis.
The Latest

Zydus Lifesciences gets FDA approval for Bortezomib for Injection

bySrinath
May 3, 2022
Total
0
Shares
0
0
0

Zydus Lifesciences (previously called Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) to market Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial.

Bortezomib for Injection is the generic of Velcade (bortezomib), which has a market size of $1.17bn as per IQVIA MAT March 2022.

It is used for the treatment of some forms of cancer that include multiple myeloma and mantle cell lymphoma.

The drug works by either slowing or stopping the growth of cancer cells.

Zydus Lifesciences gets FDA approval for Bortezomib for Injection
Zydus Lifesciences gets FDA approval for Bortezomib for Injection. Photo courtesy of Zydus Cadila.

Bortezomib for Injection will be manufactured at Zydus Hospira.

Zydus Lifesciences currently has 331 approvals and till now has submitted more than 400 abbreviated new drug applications (ANDAs) since the start of filing process in FY 2003-04.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome

Annexon Biosciences has bagged the fast track designation for its C1q inhibitor ANX005 from the US Food and Drug Administration (FDA) for the treatment of Guillain-Barré Syndrome (GBS). Considered to be a rare, acute, antibody-mediated autoimmune disease, Guillain-Barré Syndrome affects the peripheral nervous system for which there are no approved therapies in the US till […]

The post Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome appeared first on PharmaNewsDaily.com.

bypharmanewsdaily